# A Phase 2 Study to Evaluate the Efficacy and Safety of ENN0403 in Subjects with DME

> **NCT06708260** · PHASE2 · RECRUITING · sponsor: **EnnovaBio** · enrollment: 60 (estimated)

## Conditions studied

- Diabetic Macular Edema (DME)

## Interventions

- **DRUG:** ENN0403, low dose
- **DRUG:** ENN0403, high dose

## Key facts

- **NCT ID:** NCT06708260
- **Lead sponsor:** EnnovaBio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-12
- **Primary completion:** 2025-12
- **Final completion:** 2026-02
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06708260

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06708260, "A Phase 2 Study to Evaluate the Efficacy and Safety of ENN0403 in Subjects with DME". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06708260. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*